Holly Pederson, MD

Appointed
1997

Education & Fellowships

Residency - University of California San Francisco Medical Center
Internal Medicine
San Francisco, CA USA
1991

Internship - University of California San Francisco Medical Center
Internal Medicine
San Francisco, CA USA
1989

Medical Education - University of California-San Francisco School of Medicine
San Francisco, CA USA
1988

Undergraduate - University of California-Santa Barbara
Biochemistry/Molecular Biology
Santa Barbara, CA USA
1984

Additional Training

• Dr. Pederson has a special interest and subspecialty training in hereditary breast cancer.

Professional Highlights

• Research and Publications: 

   

  1. Smedira Holly Jane, “Practical Issues in Counseling Healthy Women About Their Breast Cancer Risk and
     Use of Tamoxifen Citrate,” Arch Intern Med 2000;160:3034-3042
  2. Smedira, Patrick, Rybicki and Crowe, “Integrating Medical Breast Specialists into the Traditional Breast
     Center Practice Model: A Review of 11 Years of Experience” Arch Intern Med 2008; 168:2042-2045
  3. Tan MH, Mester J, Peterson C, Yang Y, Chen JL, Rybicki LA, Milas K, Pederson H, Remzi B, Orloff MS, Eng C. “A Clinical Scoring System for Selection of Patients For PTEN Mutation Testing is Proposed on the Basis
     Of a Prospective Study of 3042 Probands” The American Journal of Human Genetics 2011: 88, 1-15
  4.  Pederson HJ, O'Rourke C, Lyons J, Patrick RJ, Crowe JP Jr, Grobmyer SR. "Time Related Changes in Yield and Harms of Screening Breast MRI" Clin Breast Cancer. 2015 Oct; 15(5): 348-352.
  5. Pederson HJ, Padia S, May M, Grobmyer S, “Management of Patients at Genetic Risk for Breast Cancer”, Cleveland Clinic Journal of Medicine 2016. 83;(3): 199-206.
  6. McCray D, Grobmyer S, Pederson H “Impact of Value Based Breast Cancer Care Pathway on Pre-Operative Breast MRI Utilization” Gland Surgery 2017 Feb; 6(1): 57-63 
  7. Donaldson AR, McCarthy C, Goraya S, Pederson HJ, Sturgis CD, Grobmyer SR, Calhoun BC, “Breast Cancer Risk Associated with Atypical Hyperplasia and Lobular Carcinoma in Situ Initially Diagnosed on Core Needle Biopsy,” Cancer 2018 Feb 1; 124 (3): 459-465.
  8. Pederson HJ, Gopalakrishnan D, Noss R, Yanda C, Eng C, Grobmyer SR, “Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients,” . J Am Coll Surg. 2018 Apr, 226(4):560-565.
  9. Pederson HJ, “Breast Cancer Risk Assessment and Treatment: Current Concepts in Genetics and Genomics,” Contemporary OB/GYN December 2017.
  10. Pederson HJ, Hussain N, Noss R, Yanda C, O’Rourke C, Eng C and Grobmyer SR “Impact of an embedded genetic counselor on breast cancer treatment,” Breast Cancer Res Treat. 2018 May;169 (1): 43-46.
  11.  Pederson HJ “Who needs breast cancer genetics testing?” OBG Manag. 2018 June; 30;(6) 34-39
  12. Grobmyer SR, Pederson HJ, Valente SA, Al-Hilli A, Radford D, Djohan R, Yetman R, Eng C and Crowe J. “Evolving Indications and Long Term Oncologic Outcomes of Risk Reducing Bilateral Nipple Sparing Mastectomy” BJS Open . 2018 Nov 26;3(2): 169-173.
  13. Pederson HJ. “Clinical care of women with intermediate breast cancer risk” Menopause. 2019 Jul; 26(7): 797-799
  14. Modesitt S, Pederson HJ, Adkins RT. “Practical Cancer Genetics and Genomics in Women’s Health”. Clin Obstet Gynecol. 2019 Jul 11.

Certifications

• Internal Medicine

Specialty Interests

Family history of breast cancer and Breast cancer risk assessment and prevention, Breast diagnostics, Benign breast disease, Breast cancer genetics and High risk management, Hereditary cancer risk management

Innovations & Patents

• Dr. Pederson helped to create the Medical Breast Program at Cleveland Clinic in 1997, and now offers a subspecialty Hereditary High Risk Clinic for patients with identified genetic mutations predisposing to breast cancer, family members of mutation carriers or patients from families with a strong family history of breast cancer. 

Memberships

• American Society of Clinical Oncology
• American Society of Breast Surgeons
• Case Comprehensive Cancer Center - Cancer Genetics Program 

See publications for Holly Pederson, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 10/8/2022, Dr. Pederson has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Pederson receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Myriad Genetics, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.